These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 31662449

  • 1. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer.
    Xiao D, Dong Z, Zhen L, Xia G, Huang X, Wang T, Guo H, Yang B, Xu C, Wu W, Zhao X, Xu H.
    Mol Cancer Res; 2020 Feb; 18(2):300-310. PubMed ID: 31662449
    [Abstract] [Full Text] [Related]

  • 2. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M.
    Cancer Lett; 2017 May 01; 393():86-93. PubMed ID: 28232049
    [Abstract] [Full Text] [Related]

  • 3. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY, Dong YP, Sun X, Sui X, Zhu H, Zhao YQ, Zhang YY, Mason C, Zhu Q, Han SX.
    Cancer Med; 2018 Nov 01; 7(11):5525-5533. PubMed ID: 30358133
    [Abstract] [Full Text] [Related]

  • 4. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
    Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R.
    Nature; 2015 Jul 09; 523(7559):177-82. PubMed ID: 26106858
    [Abstract] [Full Text] [Related]

  • 5. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Moutinho-Ribeiro P, Adem B, Batista I, Silva M, Silva S, Ruivo CF, Morais R, Peixoto A, Coelho R, Costa-Moreira P, Lopes S, Vilas-Boas F, Durães C, Lopes J, Barroca H, Carneiro F, Melo SA, Macedo G.
    Dig Liver Dis; 2022 Jul 09; 54(7):871-877. PubMed ID: 34840127
    [Abstract] [Full Text] [Related]

  • 6. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
    Moutinho-Ribeiro P, Batista IA, Quintas ST, Adem B, Silva M, Morais R, Peixoto A, Coelho R, Costa-Moreira P, Medas R, Lopes S, Vilas-Boas F, Baptista M, Dias-Silva D, Esteves AL, Martins F, Lopes J, Barroca H, Carneiro F, Macedo G, Melo SA.
    World J Gastroenterol; 2022 Aug 21; 28(31):4310-4327. PubMed ID: 36159010
    [Abstract] [Full Text] [Related]

  • 7. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J.
    Cancer Biomark; 2018 Feb 14; 21(3):505-511. PubMed ID: 29171983
    [Abstract] [Full Text] [Related]

  • 8. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL, Lan C, Pei H, Yang SN, Liu YF, Xiao LL.
    Asian Pac J Cancer Prev; 2015 Feb 14; 16(15):6569-73. PubMed ID: 26434876
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J, Zhang J.
    World J Surg Oncol; 2020 Feb 07; 18(1):31. PubMed ID: 32028958
    [Abstract] [Full Text] [Related]

  • 10. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.
    Kitagawa T, Taniuchi K, Tsuboi M, Sakaguchi M, Kohsaki T, Okabayashi T, Saibara T.
    Mol Oncol; 2019 Feb 07; 13(2):212-227. PubMed ID: 30358104
    [Abstract] [Full Text] [Related]

  • 11. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer.
    Li J, Chen Y, Guo X, Zhou L, Jia Z, Peng Z, Tang Y, Liu W, Zhu B, Wang L, Ren C.
    J Cell Mol Med; 2017 May 07; 21(5):838-847. PubMed ID: 28233416
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer.
    Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, Xiao C, Ma K, Huang X, Li Y.
    Mol Carcinog; 2019 May 07; 58(5):674-685. PubMed ID: 30604894
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis.
    Qiao Z, Wang E, Bao B, Tan X, Chen H, Wang D, Yuan L.
    Lab Med; 2024 Sep 04; 55(5):543-552. PubMed ID: 38470244
    [Abstract] [Full Text] [Related]

  • 17. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
    Goh SK, Gold G, Christophi C, Muralidharan V.
    ANZ J Surg; 2017 Dec 04; 87(12):987-992. PubMed ID: 28803454
    [Abstract] [Full Text] [Related]

  • 18. Serum Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) mRNA Protected by Exosomes as a Potential Biomarker for Gastric Cancer.
    Dong Z, Sun X, Xu J, Han X, Xing Z, Wang D, Ge J, Meng L, Xu X.
    Med Sci Monit; 2019 Oct 17; 25():7770-7783. PubMed ID: 31619663
    [Abstract] [Full Text] [Related]

  • 19. Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation.
    Yan S, Zheng H, Zhao J, Gao M, Zhang X.
    Anal Chem; 2023 Jul 11; 95(27):10196-10203. PubMed ID: 37368911
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.